HF
AVIR icon

HRT Financial’s Atea Pharmaceuticals AVIR Stock Holding History

HRT Financial’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-47,891
Closed -$170K – 3768
2025
Q4 		$170K Buy
47,891
+29,049
+154% +$92.3K ﹤0.01% 2672
2025
Q3 		$54K Buy
+18,842
New +$64.3K ﹤0.01% 2596
2023
Q4 		– Sell
-71,136
Closed -$213K – 2305
2023
Q3 		$213K Sell
71,136
-109,927
-61% -$374K ﹤0.01% 1806
2023
Q2 		$677K Buy
181,063
+73,450
+68% +$275K 0.01% 1187
2023
Q1 		$360K Sell
107,613
-25,984
-19% -$105K ﹤0.01% 1603
2022
Q4 		$642K Buy
+133,597
New +$676K 0.01% 1246

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

HRT Financial's AVIR Position: Q1 2026 in Review

HRT Financial sold out of Atea Pharmaceuticals (AVIR) in Q1 2026, closing a stake of 47,891 shares — an estimated $170K sold.

HRT Financial first reported a position in AVIR in Q4 2022 and held it in 6 quarters. The position peaked at $677K in Q2 2023. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

  • HRT Financial reported no remaining Atea Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • HRT Financial sold 47,891 Atea Pharmaceuticals shares in Q1 2026, an estimated $170K.
  • HRT Financial first reported a position in Atea Pharmaceuticals in Q4 2022 and held it in 6 quarters.
  • HRT Financial's Atea Pharmaceuticals position peaked at $677K in Q2 2023.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.